What to do with chronic pulmonary fibrosis, there is always psychological anxiety

What is the situation now; Finish.

Look at the strictness is not serious, the slight is not a big deal.

Pulmonary fibrosis is a major group of end-stage changes in lung diseases characterized by fibroblast proliferation, accumulation of a large number of extracellular matrix, and inflammation and structural destruction, that is, structural abnormalities caused by abnormal repair of normal alveolar tissue after it has been damaged.

First of all, it should be active in the primary disease that causes pulmonary fibrosis. Such as rheumatoid arthritis, dermatomyositis, systemic lupus erythematosus, etc. After the primary disease is controlled, the degree of pulmonary fibrosis can be slightly relieved.

In addition, some patients can try anti-pulmonary fibrosis drugs, such as oral pirfenidone**, but the effect is not good at this time, and some patients can also use acetylcysteine in combination with antioxidant and expectorant effects. Patients actively prevent respiratory infections and actively fight against infections when they have lung infections**. Patients are advised to receive long-term oxygen therapy, and long-acting bronchodilators can be used if necessary, which can partially improve their airway ventilation function and relieve symptoms such as chest tightness and asthma.

1.Drugs**.

1) Pirfenidone:

Pirfenidone is one of the two drugs recommended for ** in the "Clinical ** Recommended Guidelines for Idiopathic Pulmonary Fibrosis" jointly issued by the American Thoracic Society, the European Respiratory Association, the Japanese Thoracic Society and the Latin American Thoracic Society in 2015, and it is also the first ** drug approved for idiopathic pulmonary fibrosis (i.e., **unknown pulmonary fibrosis, abbreviated as IPF in English). Pirfenidone** for 52 weeks in patients with IPF slows the decline of lung function markers such as FVC and DLCO, prolongs progression-free survival (PFS), and reduces the risk of death.

2) Nintedanib: Nintedanib is one of the two drugs with the highest recommendation level (conditional recommendation) in the "Clinical ** Recommendation Guidelines for Idiopathic Pulmonary Fibrosis" jointly issued by the American Thoracic Society, the European Respiratory Association, the Japanese Thoracic Society and the Latin American Thoracic Society in 2015.

2.Non-pharmacological**.

oxygen therapy; mechanical ventilation; Lungs**; Lung transplant.

Pulmonary fibrosis is a major group of end-stage changes in lung diseases characterized by fibroblast proliferation and accumulation of a large number of extracellular matrix, accompanied by inflammatory damage and destruction of tissue structure, that is, normal alveolar tissue is damaged and repaired abnormally, resulting in structural abnormalities (scarring). The vast majority of patients with pulmonary fibrosis** are unknown (idiopathic), and this group of diseases is called idiopathic interstitial pneumonia (IIP), which is a large group of interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease that causes progressive loss of lung function [1].

Pulmonary fibrosis seriously affects the respiratory function of the human body, manifested by dry cough, progressive dyspnea (self-denial of qi), and the patient's respiratory function continues to deteriorate as the condition and lung damage worsen. The incidence and mortality of idiopathic pulmonary fibrosis are increasing year by year, and the average survival time after diagnosis is only one year, and the mortality rate is higher than that of most tumors, which is called a "tumor-like disease".